Influence of Geographical and Seasonal Variations on Carbazole Alkaloids Distribution in Murraya koenigii: Deciding Factor of Its In Vitro and In Vivo Efficacies against Cancer Cells

Table 1

Biological activity of MEF_TN.

S. No.	Cancer type	Cell lines	Mutation/drug-resistant	Culturing media + 10% FBS	MEFTN IC50 (μg/ml)
1	Ovarian	PA1	NRAS mutation anoikis-resistant	MEM	15 ± 0.2
2		OVCAR3	TP53 mutation drug-resistant	RPMI 1640	27 ± 0.18
3		SKOV3	TP53 mutation	McCoy’s 5a	16.5 ± 0.11
4		OAW42	ARID1A, PIK3CA mutation	DMEM	15.5 ± 0.05
5		UWB1.289 + BRCA1	BRCA1 mutation	MEBM + RPMI 1640 (1 : 1)	25 ± 0.2
6	Lung carcinoma	A549	KRAS, CDKN2A mutation	IMDM	13.0 ± 0.09
7	Grade IV glioblastoma	U-87 MG	PTEN mutation	IMDM	16.2 ± 0.15
8		U87MG vIII	EGFR mutation	IMDM	18.7 ± 0.02
9	Pancreatic carcinoma	MIA PaCa-2	TP53, K-RAS mutation, p16 deletion	RPMI-1640	14.1 ± 0.1
10	Colorectal	HCT116	KRAS, PIK3CA mutation	IMDM	13.4 ± 0.4
11	Cervical	Hela	STK11, CTNNB1, CNTN1 mutations	IMDM	15.45 ± 0.05
12	Squamous cell oral carcinoma	UPCI-SCC084	TP53 mutation	DMEM	14.5 ± 0.25
13		UPCI-SCC131	TP53 wild type	DMEM	15.5 ± 0.25
14	Osteosarcoma	MG63	CDKN2A mutation	MEM	14.9 ± 0.22
15	Melanoma	ChaMel47	No reports on mutation	IMDM	18.5 ± 0.21
16		Sk-mel-28	B-RAF, TP53 mutation	RPMI 1640	19 ± 0.11
17	Normal lung fibroblast cells	WI-38	—	MEM	>80 ± 0.8

Antiproliferative activity of mahanine-enriched fraction prepared from Tamil Nadu leaflets (MEF_TN) was analyzed by the MTT assay. IC50 values and mutation status of all cancers cell lines were tabulated. These data were derived from three individual experiments, and mean ± SD was indicated.